Biophytis Past Earnings Performance
Past criteria checks 0/6
Biophytis has been growing earnings at an average annual rate of 2.6%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
2.6%
Earnings growth rate
60.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Biophytis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -15 | 5 | 7 |
31 Mar 24 | 0 | -16 | 5 | 8 |
31 Dec 23 | 0 | -17 | 5 | 9 |
30 Sep 23 | 0 | -18 | 5 | 11 |
30 Jun 23 | 0 | -20 | 5 | 13 |
31 Mar 23 | 0 | -22 | 6 | 14 |
31 Dec 22 | 0 | -24 | 7 | 16 |
30 Sep 22 | 0 | -27 | 8 | 17 |
30 Jun 22 | 0 | -30 | 9 | 19 |
31 Mar 22 | 0 | -31 | 8 | 19 |
31 Dec 21 | 0 | -31 | 7 | 20 |
30 Sep 21 | 0 | -28 | 6 | 16 |
30 Jun 21 | 0 | -25 | 5 | 12 |
31 Mar 21 | 0 | -25 | 4 | 11 |
31 Dec 20 | 0 | -26 | 4 | 10 |
30 Sep 20 | 0 | -24 | 4 | 10 |
30 Jun 20 | 0 | -22 | 4 | 9 |
31 Mar 20 | 0 | -22 | 6 | 9 |
31 Dec 19 | 0 | -19 | 7 | 9 |
30 Sep 19 | 0 | -19 | 7 | 10 |
30 Jun 19 | 0 | -18 | 8 | 10 |
31 Mar 19 | 0 | -15 | 5 | 10 |
31 Dec 18 | 0 | -14 | 4 | 10 |
30 Sep 18 | 0 | -13 | 4 | 9 |
30 Jun 18 | 0 | -12 | 3 | 8 |
31 Mar 18 | 0 | -12 | 3 | 8 |
31 Dec 17 | 0 | -11 | 3 | 7 |
30 Sep 17 | 0 | -10 | 3 | 6 |
30 Jun 17 | 0 | -9 | 3 | 6 |
31 Mar 17 | 0 | -9 | 3 | 5 |
31 Dec 16 | 0 | -8 | 3 | 5 |
30 Sep 16 | 0 | -8 | 3 | 4 |
30 Jun 16 | 0 | -7 | 3 | 4 |
31 Mar 16 | 0 | -6 | 3 | 3 |
31 Dec 15 | 0 | -5 | 3 | 2 |
30 Sep 15 | 0 | -4 | 2 | 1 |
30 Jun 15 | 0 | -2 | 1 | 1 |
31 Mar 15 | 0 | -1 | 1 | 0 |
31 Dec 14 | 0 | -1 | 0 | 0 |
Quality Earnings: BPTS.Y is currently unprofitable.
Growing Profit Margin: BPTS.Y is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BPTS.Y is unprofitable, but has reduced losses over the past 5 years at a rate of 2.6% per year.
Accelerating Growth: Unable to compare BPTS.Y's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BPTS.Y is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: BPTS.Y's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.